HALBERT JON purchased $990K of CAI (indirect holdings)

HALBERT JON purchased 68,000 indirectly-held shares of Caris Life Sciences, Inc. (CAI) at $14.56 ($0.99M total) on 2026-05-15.

Original reporting
SEC EDGAR · HALBERT JON
Published Jul 13, 2026, 11:06 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 13, 2026, 11:28 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CAI
Bullish
medium confidence
Mentioned
$CAI
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CAIBullishLow
01

Why it matters

The newest fact is the disclosed open-market purchase size, price, and post-transaction share count; it does not provide new operational or financial information.

02

Market read

Traders may note insider accumulation, but the disclosure alone is unlikely to change valuation without additional company-specific catalysts.

03

What to watch

Indirect holdings and the absence of a 10b5-1 plan detail can make it harder to infer conviction or timing; the filing date lags the trade date by about two months.

Relevance 6/10Novelty 3/10Timing: filed July 13, 2026, covering a May 15, 2026 purchase

Background

The article is a SEC Form 4 insider transaction disclosure for Caris Life Sciences, Inc.

Company-level read

Ticker impact

$CAIBullishMedium confidence
Context

Caris Life Sciences director Halbert Jon filed a Form 4 showing an open-market purchase of 68,000 shares at $14.56.

Expected impact

Likely limited near-term impact; any reaction is typically modest and short-lived.

Evidence & confidence

The filing is primary-source and specific, but it does not include new company guidance, trial results, contracts, or regulatory actions.

Market effects

No clear read-across to the broader biotech/diagnostics sector from a single director open-market buy.

None indicated.

None indicated.

Counterpoint

The purchase may be routine or driven by personal liquidity planning, especially since it is indirect and not tied to a disclosed 10b5-1 plan.

Key entities

  • Caris Life Sciences, Inc.

    Company whose shares were purchased by a director via an open-market transaction disclosed on Form 4.

  • HALBERT JON

    Director reporting an indirect open-market purchase of 68,000 shares at $14.56 on May 15, 2026.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CAIMed

Caris Life Sciences Inc (CAI) Q3 2026 Earnings Call Highlights: Record Revenue, Sixth

Caris Life Sciences (CAI) reported Q3 2026 revenue growth, but faced negative free cash flow of $39.7M due to capital expenditures. Operating expenses rose $48.1M year-over-year, and full-year GAAP opex guidance was raised to ~$620M. New product launches without reimbursement may pressure margins. Q4 pharma R&D services revenue is expected to decline sequentially. The company is expanding its commercial team and expects positive free cash flow in Q4.

$CAIHigh

Caris Life (CAI) Q3 2026 Earnings Call Transcript

Caris Life (CAI) reported Q3 2026 earnings, highlighting 21% year-over-year clinical case growth and 27% revenue increase to $275M. The company launched new products, including Caris Assure for monitoring and plans to launch Caris Confirm for MRD in December. Caris Detect, their early-stage cancer detection test, is gaining market traction. The company maintained profitability with adjusted EBITDA of $44.4M and net income of $15.3M.

$CAIMed

TD Cowen raises Caris Life Sciences stock price target on pipeline

TD Cowen raised its price target for Caris Life Sciences (CAI) to $38 from $36, maintaining a Buy rating. The company reported Q3 sales beating expectations by 9%, with revenue up 85% year-over-year and a 70% gross margin. Despite this, shares fell 15% post-market due to an earnings miss. The stock has gained 65% since pre-Q2 levels, but InvestingPro suggests it may be overvalued.